PHASE 2, OPEN-LABEL, LONG-TERM, EXTENSION (OLE) STUDY OF INFIGRATINIB, AN FGFR 1-3-SELECTIVE TYROSINE KINASE INHIBITOR, IN CHILDREN WITH HYPOCHONDROPLASIA: ACCEL OLE

Registry ID

QBGJ398-205

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

QED THERAPEUTICS, INC.

Start date

2026-06-15

Last update

2025-12-08

Conditions

• HYPOCHONDROPLASIA

Related clinical trials

• A PHASE 3, OPEN-LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF VOSORITIDE IN CHILDREN WITH HYPOCHONDROPLASIA
• A PHASE 2/3, MULTICENTER, OPEN-LABEL PHASE FOLLOWED BY A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INFIGRATINIB IN CHILDREN WITH HYPOCHONDROPLASIA: ACCEL 2/3
• A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF VOSORITIDE IN CHILDREN WITH HYPOCHONDROPLASIA.

View on source registry